Adda Grimberg

Summary

Affiliation: The Children's Hospital of Philadelphia
Country: USA

Publications

  1. doi request reprint Consequences of brand switches during the course of pediatric growth hormone treatment
    Adda Grimberg
    Diagnostic and Research Growth Center, Division of Pediatric Endocrinology and Diabetes, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Endocr Pract 18:307-16. 2012
  2. ncbi request reprint IGFBP-3 mediates p53-induced apoptosis during serum starvation
    Adda Grimberg
    Division of Pediatric Endocrinology, The Children s Hospital of Philadelphia, Abramson Research Center, Philadelphia, PA 19104, USA
    Int J Oncol 21:327-35. 2002
  3. pmc Medically underserved girls receive less evaluation for short stature
    Adda Grimberg
    Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Pediatrics 127:696-702. 2011
  4. ncbi request reprint Mechanisms by which IGF-I may promote cancer
    Adda Grimberg
    University of Pennsylvania School of Medicine, Division of Pediatric Endocrinology, The Children s Hospital of Philadelphia, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA
    Cancer Biol Ther 2:630-5. 2003
  5. ncbi request reprint Somatostatin and cancer: applying endocrinology to oncology
    Adda Grimberg
    Division od Pediatric Endocrinology, The Children s Hospital of Philadelphia, Philadephia, PA 19104 4318, USA
    Cancer Biol Ther 3:731-3. 2004
  6. doi request reprint Sex-based prevalence of growth faltering in an urban pediatric population
    Adda Grimberg
    Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    J Pediatr 154:567-572.e2. 2009
  7. pmc Gender of pediatric recombinant human growth hormone recipients in the United States and globally
    Adda Grimberg
    Division of Pediatric Endocrinology, The Children s Hospital of Philadelphia, Abramson Research Center, 3615 Civic Center Boulevard, Philadelphia, PA 19104 4318, USA
    J Clin Endocrinol Metab 93:2050-6. 2008
  8. pmc Insulin-like growth factor factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling
    Adda Grimberg
    Department of Pediatrics, University of Pennsylvania School of Medicine, The Children s Hospital of Philadelphia, Pennsylvania 19104 4318, USA
    Cancer Biol Ther 5:1408-14. 2006
  9. pmc Primary pigmented nodular adrenocortical disease reveals insulin-like growth factor binding protein-2 regulation by protein kinase A
    Zonggao Shi
    Division of Pediatric Endocrinology, University of Pennsylvania School of Medicine, The Children s Hospital of Philadelphia, Abramson Research Center, Philadelphia, PA 19104 4318, USA
    Growth Horm IGF Res 17:113-21. 2007
  10. ncbi request reprint p53-Dependent and p53-independent induction of insulin-like growth factor binding protein-3 by deoxyribonucleic acid damage and hypoxia
    Adda Grimberg
    Division of Pediatric Endocrinology, The Children s Hospital of Philadelphia, Abramson Research Center, Room 802, 3615 Civic Center Boulevard, Philadelphia, Pennsylvania 19104 4318, USA
    J Clin Endocrinol Metab 90:3568-74. 2005

Research Grants

  1. Role of IGFBP -3 in mediating p53-induced apoptosis
    Adda Grimberg; Fiscal Year: 2006
  2. Overcoming Disparities in Growth Evaluations
    Adda Grimberg; Fiscal Year: 2009
  3. Overcoming Disparities in Growth Evaluations
    Adda Grimberg; Fiscal Year: 2010

Collaborators

Detail Information

Publications26

  1. doi request reprint Consequences of brand switches during the course of pediatric growth hormone treatment
    Adda Grimberg
    Diagnostic and Research Growth Center, Division of Pediatric Endocrinology and Diabetes, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Endocr Pract 18:307-16. 2012
    ..To explore the effects of insurance-mandated brand switches during the course of pediatric recombinant human growth hormone (rhGH) treatment on clinical practice...
  2. ncbi request reprint IGFBP-3 mediates p53-induced apoptosis during serum starvation
    Adda Grimberg
    Division of Pediatric Endocrinology, The Children s Hospital of Philadelphia, Abramson Research Center, Philadelphia, PA 19104, USA
    Int J Oncol 21:327-35. 2002
    ..This is the first demonstration of inhibition of p53 action by antagonizing IGFBP-3...
  3. pmc Medically underserved girls receive less evaluation for short stature
    Adda Grimberg
    Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Pediatrics 127:696-702. 2011
    ..To determine if gender is associated with diagnostic evaluation by primary care pediatricians caring for children with growth-faltering...
  4. ncbi request reprint Mechanisms by which IGF-I may promote cancer
    Adda Grimberg
    University of Pennsylvania School of Medicine, Division of Pediatric Endocrinology, The Children s Hospital of Philadelphia, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, USA
    Cancer Biol Ther 2:630-5. 2003
    ..Prompted by the accumulating evidence, investigations are also being pursued to modulate the IGF system as a possible means of cancer prevention or treatment...
  5. ncbi request reprint Somatostatin and cancer: applying endocrinology to oncology
    Adda Grimberg
    Division od Pediatric Endocrinology, The Children s Hospital of Philadelphia, Philadephia, PA 19104 4318, USA
    Cancer Biol Ther 3:731-3. 2004
    ..Potential mechanisms by which somatostatin analogs may be useful in oncology include its endocrine actions, autocrine/paracrine effects, SSTR-mediated cell signaling and SSTR-mediated cell labeling...
  6. doi request reprint Sex-based prevalence of growth faltering in an urban pediatric population
    Adda Grimberg
    Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    J Pediatr 154:567-572.e2. 2009
    ..To determine the sex-based prevalence of growth faltering in a pediatric primary care setting...
  7. pmc Gender of pediatric recombinant human growth hormone recipients in the United States and globally
    Adda Grimberg
    Division of Pediatric Endocrinology, The Children s Hospital of Philadelphia, Abramson Research Center, 3615 Civic Center Boulevard, Philadelphia, PA 19104 4318, USA
    J Clin Endocrinol Metab 93:2050-6. 2008
    ..With rhGH entering its third decade, we sought to examine U.S. gender-based treatment patterns and how these patterns compare with that of other countries...
  8. pmc Insulin-like growth factor factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling
    Adda Grimberg
    Department of Pediatrics, University of Pennsylvania School of Medicine, The Children s Hospital of Philadelphia, Pennsylvania 19104 4318, USA
    Cancer Biol Ther 5:1408-14. 2006
    ..This has significant implications for how growth hormone and IGF-I can induce growth without also inducing cancer...
  9. pmc Primary pigmented nodular adrenocortical disease reveals insulin-like growth factor binding protein-2 regulation by protein kinase A
    Zonggao Shi
    Division of Pediatric Endocrinology, University of Pennsylvania School of Medicine, The Children s Hospital of Philadelphia, Abramson Research Center, Philadelphia, PA 19104 4318, USA
    Growth Horm IGF Res 17:113-21. 2007
    ..Because alterations in the insulin-like growth factor (IGF) axis, particularly IGF-II and IGF binding protein (IGFBP)-2 overexpression, have been implicated in sporadic adrenocortical tumors, we sought to examine the IGF axis in PPNAD...
  10. ncbi request reprint p53-Dependent and p53-independent induction of insulin-like growth factor binding protein-3 by deoxyribonucleic acid damage and hypoxia
    Adda Grimberg
    Division of Pediatric Endocrinology, The Children s Hospital of Philadelphia, Abramson Research Center, Room 802, 3615 Civic Center Boulevard, Philadelphia, Pennsylvania 19104 4318, USA
    J Clin Endocrinol Metab 90:3568-74. 2005
    ..Because IGFBP-3 can inhibit growth and induce apoptosis in IGF-dependent and IGF-independent manners, its induction by DNA damage and hypoxia suggest IGFBP-3 plays a role in the physiologic protection against aberrant cell growth...
  11. ncbi request reprint Alterations in the expression of insulin-like growth factors and their binding proteins in lung cancer
    Carrie M Coleman
    Division of Endocrinology and Diabetes, Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Methods Mol Med 74:167-86. 2003
  12. ncbi request reprint Sex differences in patients referred for evaluation of poor growth
    Adda Grimberg
    Division of Pediatric Endocrinology, Department of Pediatrics, The Children s Hospital of Philadelphia, Abramson Research Center, PA 19104 4318, USA
    J Pediatr 146:212-6. 2005
    ..The objective of this study was to compare sex differences among referrals for evaluation of poor growth...
  13. doi request reprint Internet informs parents about growth hormone
    Pamela Cousounis
    Division of Pediatric Endocrinology and Diabetes, The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Horm Res Paediatr 80:86-91. 2013
    ..Parents' knowledge influences decisions regarding medical care for their children...
  14. ncbi request reprint Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3
    Munenori Takaoka
    Gastroenterology Division, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104 2144, USA
    Cancer Res 64:7711-23. 2004
    ..In aggregate, we have identified for the first time that IGFBP-3 is an aberrantly regulated gene through the EGFR signaling pathway and it may modulate EGFR effects during carcinogenesis...
  15. ncbi request reprint Measuring growth hormone and insulin-like growth factor-I in infants: what is normal?
    Colin Patrick Hawkes
    Division of Endocrinology and Diabetes, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Pediatr Endocrinol Rev 11:126-46. 2013
    ..In this review, we summarize our current understanding of normal GH and IGF-I secretion in children under 18 months of age, and describe variations in the reported assay-specific measurements...
  16. ncbi request reprint Endocrine phenotype of 6q16.1-q21 deletion involving SIM1 and Prader-Willi syndrome-like features
    Kosuke Izumi
    Division of Human Genetics, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania
    Am J Med Genet A 161:3137-43. 2013
    ..Hence, we suggest that detailed endocrine evaluation and longitudinal endocrine follow up be performed in individuals with proximal interstitial 6q deletion involving SIM1...
  17. ncbi request reprint Cancer
    Adda Grimberg
    The Children s Hospital of Philadelphia, PA 19104 4318, USA
    Adv Exp Med Biol 567:305-39. 2005
  18. pmc Pathologic lower extremity fractures in children with Alagille syndrome
    Christina B Bales
    Department of Pediatrics, The Department of Biostatistics and Epidemiology at the University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    J Pediatr Gastroenterol Nutr 51:66-70. 2010
    ..In this retrospective study, we aimed to determine the incidence and distribution of fractures in patients with Alagille syndrome, 1 of the leading inherited causes of pediatric cholestatic liver disease...
  19. ncbi request reprint Expanded spectrum of recombinant human growth hormone therapy
    Maria J Henwood
    Division of Pediatric Endocrinology, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 4318, USA
    Curr Opin Pediatr 14:437-42. 2002
    ..Although recent investigations provide encouraging short-term data, it is important to recognize that the impact of recombinant human growth hormone therapy on adult height has not been established in a number of conditions...
  20. pmc Energy expenditure in obesity associated with craniopharyngioma
    Roy J Kim
    Division of Endocrinology, Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Childs Nerv Syst 26:913-7. 2010
    ..Obesity is a common yet incompletely understood complication of childhood craniopharyngioma. We hypothesized that craniopharyngioma is associated with specific defects in energy balance compared to obese control children...
  21. ncbi request reprint Pediatric brain tumor treatment: growth consequences and their management
    Sogol Mostoufi-Moab
    Department of Pediatrics, Divisions of Endocrinology and Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Pediatr Endocrinol Rev 8:6-17. 2010
    ..Therefore, a thorough understanding of the epidemiology and pathophysiology of growth failure as a consequence of childhood brain tumor, both during and after treatment, is necessary and the main focus of this review...
  22. pmc Dysregulated editing of serotonin 2C receptor mRNAs results in energy dissipation and loss of fat mass
    Yukio Kawahara
    The Wistar Institute, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Neurosci 28:12834-44. 2008
    ..Our results highlight the importance of regulated 5-HT(2C)R mRNA editing, because dysregulation could result in the pathological consequences such as growth retardation seen in VGV mice...
  23. ncbi request reprint Non-invasive fluorescence imaging of cell death in fresh human colon epithelia treated with 5-Fluorouracil, CPT-11 and/or TRAIL
    Niklas Finnberg
    Abramson Comprehensive Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer Biol Ther 4:937-42. 2005
    ..The results support the feasibility of developing non-invasive optical imaging strategies to detect apoptosis through direct visualization of injury to human colonic epithelia in vivo...
  24. pmc Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab
    Lori S Hart
    Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Cell Cycle 10:2331-8. 2011
    ..Our results suggest that CP-751,871 has preferential activity against putative CSC populations and, therefore, may complement current standard chemotherapeutic regimens that target cycling cells...
  25. ncbi request reprint Reconciling diabetes management and the ketogenic diet in a child with pyruvate dehydrogenase deficiency
    Maria J Henwood
    Division of Pediatric Endocrinology, Columbus Children s Hospital, Columbus, Ohio, USA
    J Child Neurol 21:436-9. 2006
    ..Her progress to date indicates that diabetes does not preclude use of the ketogenic diet...
  26. ncbi request reprint PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease
    Olga T Hardy
    Division of Endocrinology and Diabetes, The Children s Hospital of Philadelphia, Philadelphia, PA 19104 4318, USA
    Pediatr Emerg Care 22:52-4. 2006
    ..Subsequent treatment of persistent hyperthyroidism with radioablation did not result in an exacerbation of the vasculitis, a complication described in prior case reports...

Research Grants3

  1. Role of IGFBP -3 in mediating p53-induced apoptosis
    Adda Grimberg; Fiscal Year: 2006
    ..These studies also reflect Dr. Grimberg?s long-term career goals of exploring the interrelatedness of endocrine and oncologic molecular biology principles and applying them to clinical problems of dysregulated growth. ..
  2. Overcoming Disparities in Growth Evaluations
    Adda Grimberg; Fiscal Year: 2009
    ....
  3. Overcoming Disparities in Growth Evaluations
    Adda Grimberg; Fiscal Year: 2010
    ....